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P R E V I E W SFat uses a TOLL-road to connect inflammation
and diabetes
The link between inflammation and diabetes is well established, but the nature of the link is unresolved. Obesity, inflamma-
tion, and insulin resistance are major characteristics of diabetes. A study by Flier and colleagues (Shi et al., 2006) identifies
Toll-like receptor 4 signaling activated by fatty acids as part of that link. This receptor mediates inflammatory events and
insulin resistance in peripheral organs.More than a century ago, Williamson and
Lond reported the beneficial effects of
sodium salicylate on the treatment of
glycosuria and diabetes (Williamson and
Lond, 1901). The interesting effect of an
anti-inflammatory agent on diabetes
was confirmed in 1957 when Reid and
colleagues showed improvement in oral
glucose tolerance in aspirin-treated dia-
betic patients (Reid et al., 1957). The
potential relationship between inflamma-
tion and diabetes was silenced by the
ground-breaking discovery of Randle’s
‘‘Glucose Fatty-Acid Cycle’’ (Randle
et al., 1963), which was the first mecha-
nism that described fatty acid-induced
insulin resistance. Further fueled by
McGarry’s insightful views that highlight
the importance of lipid disorder in diabe-
tes (McGarry, 1992), much of the late
20th-century diabetes research was di-
rected to identifying adipocyte genes
associated with lipid metabolism as the
main causative factor of insulin resis-
tance. This effort led to the discoveries of
obese (ob) gene by Zhang and Friedman
(Zhang et al., 1994) and a host of adipo-
cyte-derived hormones, such as leptin,
adiponectin, and resistin, that redefined
the endocrine and metabolic role of adi-
pose tissue. The latest effort is high-
lighted in an article from Shi and Flier
(Shi et al., 2006), who report the key role
of Toll-like receptor 4 on lipid-induced
activation of inflammatory and metabolic
signaling in insulin resistance and againCELL METABOLISM : DECEMBER 2006raise the question on the link between
obesity, innate immunity, and diabetes.
Studies investigating the relationship
between obesity and insulin resistance
unveiled two significant observations that
generated an enormous interest in the
role of inflammation in diabetes. First, in
addition to energy-regulating hormones,
adipose tissue releases proinflammatory
cytokines, including TNF and IL-6. Lang
observed that TNF causes insulin resis-
tance in peripheral organs (Lang et al.,
1992), and Hotamisligil and Spiegelman
delineated a mechanism that involved
TNF-a-mediated serine phosphorylation
of IRS-1 (Hotamisligil and Spiegelman,
1994). Subsequent findings that adipo-
cyte production of TNF-a was increased
in obese subjects identified TNF-a as
an important component of the obesity-
diabetes link. IL-6 is another proinflam-
matory cytokine that is produced by adi-
pocytes, elevated in obese subjects,
and shown to alter glucose metabolism
in peripheral organs (Kim et al., 2004).
Second, studies of the complex net-
workof insulin signalingandobservations
of impaired insulin signaling in diabetic
organssuggested thatmechanismsother
than the Glucose Fatty-Acid Cycle medi-
ate FFA-induced insulin resistance. This
search led to the discovery of at least
three inflammation-associated proteins
that are involved in the cross-talk be-
tween inflammatory and metabolic path-
ways. Shulman (Shulman, 2000) demon-strated that intracellular accumulation of
lipid metabolites (fatty acyl CoAs, DAG,
ceramides) activates PKC-q, which
causes serine phosphorylation of IRS-1
and insulin resistance in skeletal muscle.
Also, FFAs activate IKK/NF-kB, and Yuan
and Shoelson (Yuan et al., 2001) showed
that salicylate-mediated inhibition of IKK
attenuates lipid-induceddefects in insulin
signaling and insulin resistance. Their
findings present a molecular explanation
to the earlier observations of Williamson
andReid. Lastly, Hirosumi andHotamisli-
gil (Hirosumi et al., 2002) reported that
c-Jun amino-terminal kinases (JNKs),
which are activated by inflammatory cy-
tokines and lipids, impair insulin signaling
and mediate obesity-associated insulin
resistance. Together, the findings support
the triangular relationship between obe-
sity, inflammation, and insulin resistance.
In the article of Shi and Flier (Shi et al.,
2006), the investigators present Toll-like
receptor 4 (TLR4) as the link between in-
nate immunity, lipid, and insulin resis-
tance. Toll-like receptors, a family of
pattern-recognition receptors, play an
important role in the innate immune sys-
tem, and the authors show that TLR4 is
expressed in many cell types including
macrophages, adipocytes, liver and
skeletal muscle. Binding of LPS to TLR4
recruits the adaptor protein myeloid
differentiation factor 88 (MyD88) which
leads to activation of NF-kB associ-
ated genes that encode inflammatory417
P R E V I E W Scytokines, such as TNF-a and IL-6.
Recent studies indicate that adipocytes
in obese subjects manifest macro-
phage-like properties including cytokine
production and activation of chronic
inflammatory state that are partly due to
infiltration of macrophages in adipose
tissue (Wellen and Hotamisligil, 2005). In
this regard, Shi and Flier hypothesized
that TLR4 mediates lipid-induced activa-
tion of inflammatory signaling and insulin
resistance in peripheral organs.
The authors demonstrate that fatty
acids, particularly saturated fatty acids
(C14:0, C16:0, and C18:0), activate the
IKK/NF-kB pathway and stimulate mac-
rophage production of TNF-a and IL-6,
dependent on TLR4 signaling. 293T
cells transfected with dominant-negative
MyD88 or peritoneal macrophages iso-
lated fromTLR42/2mice showedblunted
cytokine production in response to FFA
treatment. The authors also found ele-
vated adipocyte expression of TLR4 in
obese rodent models (ob/ob, db/db,
and diet-induced obese mice). More-
over, FFA-induced expression of TNF-a
and IL-6 was attenuated in the adipo-
cytes of TLR42/2 mice. The authors
tested their hypothesis in vivo by apply-
ing an acute lipid infusion to promote
FFA-induced insulin resistance in periph-
eral organs and performing hyperinsuli-
nemic-euglycemic clamps in TLR42/2
mice. Lipid infusion activated nuclear
translocation of NF-kB and increased the
production of TNF-a and IL-6 in wild-type
adipocytes; these lipid-mediated effects
weremarkedly blunted in TLR42/2 adipo-
cytes. TLR4 deficiency attenuated lipid-
induced serine307 phosphorylation of
IRS-1 and normalized insulin-stimulated
IRS-1 tyrosine phosphorylation. Physio-
logical role of TLR4 was demonstrated
using chronic high-fat feeding in female
TLR42/2 mice. TLR4 deletion partly pre-
vented diet-induced insulin resistance
despite increased adiposity in the null
mice, and these effects were associated
with reduced expression of TNF-a, IL-
6, SOCS3, MCP-1, and the macrophage
marker F4/80 in adipose tissue and liver
of high-fat fed TLR42/2 mice. Taken to-
gether, these findings strongly support
the role of TLR4 as a mediator of lipid-in-
duced activation of inflammation and in-
sulin resistance.
It is clear that many factors mediate
obesity-associated insulin resistance. In-
hibition of TNF-a, IKK, PKC, JNK, and
SOCS3 as well as a decrease in fatty418Figure 1. TLR4 mediates FFA-induced activation of inflammatory and metabolic signaling in insulin resistance
FFAs bind to TLR4 to activate IkB-kinase (IKK), which causes degradation of IkBa and stimulates nuclear trans-
location and expression of NF-kB associated genes such as IL-6 and tumor necrosis factor (TNF)-a. Activated
IKK, c-Jun amino-terminal kinase (JNK), and protein kinase C (PKC) directly increase serine phosphorylation of
insulin receptor substrate (IRS) that downregulates insulin signaling associatedwith IRS tyrosine phosphorylation,
PI 3-kinase (PI3K), PDK, andAkt, resulting in reducedglucose transport into cells (insulin resistance). FFA-induced
activation of TLR4/IKK/NF-kB and production of IL-6 and TNF-a further downregulate insulin signaling via sup-
pressor of cytokine signaling 3 (SOCS3) and JNK and indirectly cause insulin resistance in peripheral organs.acids all improve insulin sensitivity. A
significant implication of Shi and Flier’s
findings is that TLR4 may be one gate-
way by which fatty acids impact in-
flammation and metabolism. In this sce-
nario, increased fatty acids, as found in
obese subjects, activate TLR4 signaling
in macrophages, adipocytes, and liver.
This directly activates IKK, JNK, PKC,
and SOCS3, which leads to serine phos-
phorylation of IRS proteins and im-
paired insulin signaling and action. Lipid-
induced activation of TLR4 and IKK/
NF-kB also increases local production
of TNF-a and IL-6 that indirectly attenu-
ates insulin action in other organs (Fig-
ure 1). However, the authors’ findings
pose noteworthy questions. TLR4 dele-
tion increased food intake, suggesting
the potential role of CNS circuitry on
metabolism. A direct versus indirect role
as well as macrophage-independent
effects of TLR4 on insulin resistance
need to be addressed by generating tis-
sue-specific KO mice. It is also puzzling
that insulin sensitivity phenotypes are
evident in female TLR42/2 mice but not
in male null mice despite blunted diet-
induced inflammatory gene expression.For future targeting strategy, it will be
important to identify a TLR4 inhibitor
that affects the ‘‘bad’’ metabolic arm of
signaling without impacting the ‘‘good’’
inflammation arm of the pathway. Over-
all, TLR4 is an appealing answer to a
century-old question on the link between
obesity, inflammation, and insulin resis-
tance, and their findings will lead to
uncovering new therapeutic targets to
fight this old disease.
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Bone formation is controlled by a netwo
(2006), studying the role of the transcripti
demonstrate striking effects of changing
Genetic analyses in humans and mice
have uncovered transcription factors
that control osteoblast differentiation
and bone formation through enhancing
(e.g., Runx2 and Osterix) or diminishing
(e.g., Twist) the expression of target
genes (Karsenty and Wagner, 2002).
Other genetic mutations pinpoint previ-
ously unrecognized pathways of control
of bone formation. For example, activa-
tion of Lrp5 (a component of the Wnt sig-
naling complex) results in a rare high
bone-mass syndrome; inactivation of
Lrp5 is accompanied by severe osteo-
porosis. Genetic inactivation of SOST
results in another rare ‘‘big-bone’’ syn-
drome—SOSTencodes theprotein prod-
uct sclerostin, which is localized in bone
to the osteocyte and operates as a
powerful inhibitor of bone formation.
Novel aspects of transcriptional con-
trol of bone development are reported
in this issue of Cell Metabolism by Elef-
teriou et al. (2006), showing quite re-
markably that the increased bone-mass
phenotype resulting from neurofibromin
(Nf1) deficiency can be rescued through
nutritional restriction of protein intake. In
addition, the opposite skeletal pheno-
type, Atf4 deficiency, which is analogous
to Coffin-Lowry syndrome, can be res-
cued by high protein feeding.
These authors had shown previously
that mice null for either the transcription
factor Atf4 or its essential activating
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rk of transcription factors and signaling m
on factor ATF4 in a new mouse model of ne
dietary protein on bone formation abnorm
kinase, Rsk2, exhibited greatly impaired
bone formation, with reduced numbers
and thickness of bone trabeculae (Yang
et al., 2004). The defect in bone formation
continued postnatally, after having be-
come obvious relatively late in fetal
development. Type I collagen protein
synthesis was decreased almost 10-fold
in Atf42/2 osteoblasts, even though ex-
pression of a(I) collagen was unchanged.
Notably, the defect in collagen produc-
tion was corrected in vitro by addition of
nonessential amino acids, indicating
that the failed collagen production re-
sulted from a posttranscriptional effect.
This revealed in osteoblasts a regulatory
role of ATF4 in amino acid transport that
had been recognized in other cell types
(Harding et al., 2003).
In the present work (Elefteriou et al.,
2006), the authors used a mouse model
to investigate the skeletal phenotype
seen in patients with neurofibromatosis
type 1, which results from deficiency
of the Nf1 protein product, a tumor-
suppressor protein. Skeletal abnormali-
ties in these patients include bowing of
the long bones and pseudoarthroses
and increase with age (Ruggieri et al.,
1999). Since ablation of Nf1 in mice
is embryonic lethal and since Nf1 was
found to be amply expressed in osteo-
blasts, the authors chose to prepare
mice in which Nf1 was ablated specifi-
cally in osteoblasts.Williamson, R.T., and Lond, M.D. (1901). BMJ 1,
760–762.
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olecules. In this issue, Elefteriou et al.
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alities.
In the Nf1ob
2/2 mice, bone volume in-
creased progressively starting soon after
birth, with quantitative histomorphome-
try showing increases in osteoblast sur-
face and number, osteoid amount, and
bone formation rate (Figure 1). Addition-
ally, bone resorption was increased,
with increased osteoclasts in bone and
excretion of a marker of bone resorption.
Importantly, the enhanced osteoclast
formation was not cell autonomous but
required coculture of Nf1-deficient oste-
oblasts with wild-type hematopoietic
cells. Thus, the phenotype appeared to
be the opposite of that accompanying
Atf4 or Rsk2 deficiency.
The critical clue, however, came
frommolecular studies in bone and oste-
oblasts: production of type I collagen
protein was increased despite normal
collagen mRNA in osteoblasts and bone
of Nf1ob
2/2 mice. Although the amount of
ATF4 was not increased in the bones
of mutant mice, its activation by its cru-
cial kinase, RSK2, was enhanced, lead-
ing to the conclusion that NF1 acts in
the osteoblast to limit phosphorylation
of ATF4 by RSK2 and, in so doing, limits
expression of osteocalcin as well as the
transport of amino acids necessary for
the synthesis of the most abundant pro-
tein in bone, type I collagen. Confirma-
tion of the mechanism came by over-
expressing Atf4 in osteoblasts and
generating mice that recapitulated the
419
